Treatment of Tendinosis Using the TenJet Hydroresection System
Launched by ROTHMAN INSTITUTE ORTHOPAEDICS · Apr 25, 2022
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is 18 - 70 years of age
- • Chronic tendon pain ≥ 3 months duration
- • History and clinical examination consistent with tendinosis
- • Sonographic or MRI confirmation of tendinosis
- • 3 months of conservative treatment
- • Patient is willing and able to provide informed consent and comply with the study protocol
- Exclusion Criteria:
- • Full thickness tear of the tendon
- • Unable to withhold anticoagulants 7 days prior to the procedure.
- • Use above 81mg/day of acetylsalicyclic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 7 days of treatment
- • Steroid, PRP, Stem cell or biologic injections within 3 months of the study procedure date
- • Needle tenotomy, Tenex, or surgical interventions within 6 months of study procedure date
- • Active local or systemic infection requiring antiviral, antibacterial or antifungal treatment
- • Chronic conditions such as CRPS or fibromyalgia that might affect pain symptoms.
About Rothman Institute Orthopaedics
Rothman Institute Orthopaedics is a leading healthcare organization specializing in orthopedic care and research. With a commitment to advancing the field of orthopedics, Rothman Institute conducts innovative clinical trials aimed at improving patient outcomes and enhancing treatment methodologies. Renowned for its team of highly skilled orthopedic surgeons and researchers, the institute integrates cutting-edge technology and evidence-based practices to deliver exceptional care. Through its rigorous research initiatives, Rothman Institute is dedicated to fostering advancements in orthopedic medicine and contributing to the overall improvement of musculoskeletal health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Baton Rouge, Louisiana, United States
Chapel Hill, North Carolina, United States
Redwood City, California, United States
Coral Springs, Florida, United States
Lorain, Ohio, United States
Clarion, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials